Teachers Retirement System of The State of Kentucky Sells 1,258 Shares of Hologic, Inc. (NASDAQ:HOLX)

Teachers Retirement System of The State of Kentucky reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,674 shares of the medical equipment provider’s stock after selling 1,258 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Hologic were worth $1,440,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the period. Black Creek Investment Management Inc. increased its position in Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after buying an additional 885,524 shares during the last quarter. Mackenzie Financial Corp raised its stake in Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after buying an additional 815,960 shares during the period. Marshall Wace LLP acquired a new stake in shares of Hologic in the second quarter valued at approximately $39,427,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after acquiring an additional 450,190 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 0.2 %

Shares of NASDAQ HOLX opened at $72.26 on Wednesday. The stock has a market capitalization of $16.40 billion, a P/E ratio of 21.70, a PEG ratio of 2.38 and a beta of 0.96. The stock’s fifty day moving average is $79.01 and its 200 day moving average is $78.62. Hologic, Inc. has a 52 week low of $70.24 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the firm earned $0.89 EPS. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.75% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HOLX. Royal Bank of Canada increased their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Evercore ISI increased their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Leerink Partners lowered their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus price target of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.